What is Axsome Therapeutics's license — cost of revenue?

Axsome Therapeutics (AXSM) reported license — cost of revenue of $1M in Q2 2023.

What does license — cost of revenue mean?

The direct expenses incurred to earn revenue from licensing out intellectual property.

How do you interpret license — cost of revenue?

A lower cost relative to licensing revenue indicates higher margins on partnership deals, whereas rising costs may signal unfavorable royalty structures or increased compliance burdens.

How does license — cost of revenue compare across companies?

Varies significantly based on whether the company owns the underlying IP outright or owes royalties to academic institutions or previous research partners.

Axsome Therapeutics AXSM License — Cost Of Revenue

Discontinued — last reported Q2 '23

Similar metrics at other companies

BRKRLicense — Cost Of Revenue

$2.48M-2.0%

BBIOCost Of License And Services Revenue — Cost Of Revenue

$605K+1.2%

MRNALicense agreement — Cost of Sales

$400M—

PTCLicense — Cost Of License Revenue

$12.02M+9.9%

WMGLicense — Cost of Goods Sold

$16.97K+511%

FROGLicense — Cost Of Revenue

$0-100%

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The official record: Axsome Therapeutics’s 10-Q, filed August 7, 2023, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's license — cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's license — cost of revenue?: Axsome Therapeutics (AXSM) reported license — cost of revenue of $1M in Q2 2023.
What does license — cost of revenue mean?: The direct expenses incurred to earn revenue from licensing out intellectual property.
How do you interpret license — cost of revenue?: A lower cost relative to licensing revenue indicates higher margins on partnership deals, whereas rising costs may signal unfavorable royalty structures or increased compliance burdens.
How does license — cost of revenue compare across companies?: Varies significantly based on whether the company owns the underlying IP outright or owes royalties to academic institutions or previous research partners.